References
Haimovich J, David HM, Schreiber AB (1990) Human antimouse immunoglobulins in sera of patients treated chronically with monoclonal antibody purified Factor VIII. Semin Hematol 27 [Suppl 2]: 11–15
Kasper CK (1984) Measurement of Factor VIII inhibitors. Progr Clin Biol Res 150: 87–98
Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner M, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J (1975) A more uniform measurement of Factor VIII inhibitors. Thromb Diath Haemorrh 34: 875–876
Lusher JM, Salzman PM, Monoclate Study Group (1990) Viral safety and inhibitor development associated with Factor VIII C ultra-purified from plasma in hemophiliacs previously unexposed to Factor VIII C concentrates. Semin Hematol 27 [Suppl 2]: 1–7
Mannucci PM, Colombo M (1988) Virucidal treatment of clotting factor concentrates. Lancet II: 782–785
Mannucci PM, Colombo M (1989) Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis. Thromb Haemost 61: 532–534
Mannucci PM, Schimpf K, Brettler D, Colombo M, Lechner K, Lusher JM, Roberts H (1991) Hepatitis C virus is not transmitted by a high purity, pasteurized Factor VIII concentrate. Ann Intern Med 113: 27–32
Schimpf K, Mannucci POM, Kreutz W, Brackmann HH, Auerswald G, Ciavarella N, Mösseler J, De Rosa V, Kraus B, Brueckmann C, Mancuso G, Mittler U, Haschke F, Morfini M (1987) Absence of hepatitis after treatment with a pasteurized F VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 316: 918–922
Author information
Authors and Affiliations
Additional information
It should be noted that not all of the tests listed relate to hepatitis; additional surveillance for other possible complications of treatment are included as well
Rights and permissions
About this article
Cite this article
Lusher, J.M. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol 63, 138–141 (1991). https://doi.org/10.1007/BF01703244
Issue Date:
DOI: https://doi.org/10.1007/BF01703244